SAN DIEGO and ZURICH, Switzerland, Sept. 13, 2012 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. APRI and Takeda Pharmaceuticals International GmbH jointly announced today that they have entered into an exclusive license agreement to market Vitaros®, a treatment for erectile dysfunction, in the UK.
See full press release
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in
